Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine combined with SSRIs for major depressive disorder
ChiCTR2000032518Phase 4Recruiting
- Sponsor
- Shandong Mental Health Center
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of agomelatine, sertraline and escitalopram in major depressive disorder (MDD) (2 arms), sponsored by Shandong Mental Health Center. Primary endpoint: Hamilton Depression Scale at week 12. Started Jan 2020; status: recruiting.
02
Drugs
agomelatinesertralineescitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2000032518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032518.